Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q2

4564.TEDINET S100S8MF
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥356m2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥515m2022-04-01 → 2022-09-30Cons.Net sales
Operating income−¥695m2023-04-01 → 2023-09-30Cons.Operating income
Operating income−¥618m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income−¥708m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥1.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥644m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥709m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax−¥613m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥711m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.1bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥614m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥711m2023-04-01 → 2023-09-30Cons.Profit loss
Net income−¥614m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.2bnat 2023-09-30Cons.Assets
Total assets¥1.5bnat 2023-03-31Cons.Assets
Total assets¥1.7bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥233mat 2023-09-30Cons.Liabilities
Total liabilities¥656mat 2023-03-31Cons.Liabilities
Net assets / equity¥935mat 2023-09-30Cons.Net assets
Net assets / equity¥855mat 2023-03-31Cons.Net assets
Net assets / equity¥1.3bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥881mat 2023-09-30Cons.Cash and deposits
Cash and deposits¥1.1bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥881mat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥1.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.8bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥880m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥795m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥517m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥34m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥20m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥677m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥96m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-3.422023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.452023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.812022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.192022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.742022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio73.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio51.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio76.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥183m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥109m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥537,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥387,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥149,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥403m
—segment totalrevenue2023-04-01 → 2023-09-30¥357m
—segment totalrevenue external2023-04-01 → 2023-09-30¥356m
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥149,000
—segment totalsegment profit2023-04-01 → 2023-09-30−¥512m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥188m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥48m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥111,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-09-30−¥382m
—segment totalrevenue2022-04-01 → 2022-09-30¥515m
—segment totalrevenue external2022-04-01 → 2022-09-30¥515m
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥111,000
—segment totalsegment profit2022-04-01 → 2022-09-30−¥430m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 421
ItemContextValueUnit
Proceeds from collection of lease and guarantee deposits inv cfPrior1YTDDuration－JPY
Proceeds from collection of lease and guarantee deposits inv cfCurrentYTDDuration39456000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-6633000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-33570000JPY
Proceeds from issuance of common stock fin cfPrior1YTDDuration－JPY
Proceeds from issuance of common stock fin cfCurrentYTDDuration683770000JPY
Repayments to share acquisition rights fin cfPrior1YTDDuration－JPY
Repayments to share acquisition rights fin cfCurrentYTDDuration-6540000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration－JPY
Net cash provided by used in financing activitiesCurrentYTDDuration677229000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration-523353000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration-236192000JPY
Cash and cash equivalentsPrior2YearInstant1836906000JPY
Cash and cash equivalentsPrior1YearInstant1117635000JPY
Cash and cash equivalentsPrior1QuarterInstant1313552000JPY
Cash and cash equivalentsCurrentQuarterInstant881443000JPY
Taxes and dues sgaPrior1YTDDuration68089000JPY
Taxes and dues sgaCurrentYTDDuration72125000JPY
Commission fee sgaPrior1YTDDuration45185000JPY
Commission fee sgaCurrentYTDDuration39969000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember7885000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember506680000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember514566000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration514566000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember111000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember111000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-111000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember7996000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember506680000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember514677000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-111000JPY
Net salesPrior1YTDDuration514566000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember-382023000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember-48050000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember-430073000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-188004000JPY
Operating incomePrior1YTDDuration-618078000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember387000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember356064000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember356452000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration356452000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember149000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember149000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-149000JPY
Transactions with other segmentsCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass